Lawrence Fong

MD

Genitourinary oncologist
Cancer immunotherapy program leader and lab researcher

About me

Dr. Lawrence Fong is a specialist in genitourinary cancer at UCSF Medical Center. He is particularly interested in tumor immunology – the role of the immune system in cancer – and developing immune-based treatments. He earned his undergraduate degree from Columbia University and his medical degree from Stanford University. He completed an oncology fellowship at Stanford, then joined the medical staff there in 1999. Fong came to UCSF in 2002.

  • Education

    Stanford University, 1992

  • Residencies

    University of Washington, Internal Medicine, 1994

  • Fellowships

    Stanford University, Oncology, 1997

  • Academic Title

    Professor

My goal is to improve treatment of cancer through immunotherapy.

Cancer Immunotherapy Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fifth Floor
San Francisco, CA 94158

Genitourinary Medical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

Prostate Cancer Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

Decorative Caduceus

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Adv...

Recruiting

Decorative Caduceus

Pembrolizumab in Combination With Intratumoral SD-101 Therapy

To determine the rate of PSA < nadir + 2 ng/mL at 15 and 24 months in patients with non-castrate levels of testosterone in each study arm.

Recruiting

Decorative Caduceus

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Infor...

Recruiting

Decorative Caduceus

Neoadjuvant Atezolizumab With or Without Enzalutamide in Localized Prostate Cancer Given Before...

The proportion of subjects with positive responses will be reported with 95% confidence intervals.

Recruiting

Decorative Caduceus

Neoadjuvant Atezolizumab in Localized Bladder Cancer

The immunologic effect MPDL3280A activity within bladder tissue will be measured by a change in the CD3+ T cell count/µm2 between pretreatment biopsy and cystectomy tissue following MPDL3280A infusions. Tissue will be designated i...

Recruiting

Decorative Caduceus

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combinati...

Recruiting

Decorative Caduceus

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Da...

Objective response rate (ORR) in mCRPC subjects with proficient DNA damage repair (Group 1) and defective DNA damage repair (Group 2), using immune-related response criteria (irRC)

Recruiting

Decorative Caduceus

Study of HPN424 in Patients With Advanced Prostate Cancer

In Part 1, measure incidence of dose limiting toxicities measured by adverse events and serious adverse events by dose level.

Recruiting

Decorative Caduceus

A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants Wit...

Recruiting

Share